
CLAIMS

1. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide.

2. The salt of Claim 1, wherein the salt is described by Formula (II)



(II).

3. The salt of Claim 1 in a non-hydrate form.

4. The salt of Claim 1 in a hydrate form.

5. A pharmaceutical composition comprising:




(a) a therapeutically effective amount of a salt according to any of claims 1-4; and



(b) at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient.

6. The use of a therapeutically effective amount of a salt according to any of claim 1-4 in the manufacture of a medicament for the treatment of breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer, bladder cancer, renal cancer, brain cancer, gastric cancer, hyperplasia, stomach cancer, colon cancer, larynx cancer, lymphatic system cancer, genitourinary tract cancer, bone cancer, prostate cancer, small-cell lung cancer, glioma cancer, colorectal cancer, kidney cancer, epidermas cancer, liver cancer, esophagus cancer, hematopoietic cancer, lympnoma, myeloma, thyroid follicular cancer, fibrosarcoma, habdomyosarcoma, astrocytoma, neuroblastoma, glioma, schwannoma, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoctanthoma,

thyroid follicular cancer, Kaposi's sarcoma, chronic lymphocytic leukaemia, mantle cell lymphoma, large B cell lymphoma.



7. A method of preparing the compound of Formula (I) comprising

(1) reacting  and  to form , and


(2) converting the  to .

8. The method of claim 7, wherein step (1) is performed in the presence of $Pd(OAc)_2$, BINAP, and Cs_2CO_3.

9. The method of claim 7, wherein step (2) is performed in the presence of HCl(aq.) and toluene.


10. The method of claim 7, wherein the  is further converted to .

11. The method of claim 10 where in the conversion takes place in the presence of IPA and




.



12. A method of preparing the compound of Formula (III):





(III)



comprising converting .


13. The method of claim 12, wherein the conversion of the  takes place in the presence of MnO_2, NaCN, , and THF.

14. The method of claim 12 wherein the  is formed from






.



15. A method of preparing the compound of Formula (III):







(III)

comprising:


(1) reacting  and  to form ,

(2) converting the  to form ,

(3) converting the  to form , and




(4) converting the  to form .



16. A method of preparing the compound of Formula (IV):





(IV)

comprising


(1) reacting  with  to form ,

(2) converting the  to form , and

(3) converting the  to form .




17. The method of claim 16 wherein the reaction takes place in the presents of n-BuOH.



18. A method of preparing the compound of Formula (IV):



(IV)

comprising:

(1) reacting  with  to form , and

(2) further converting the  to form .

Claims

1. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide characterized by the initial X-ray Powder Diffraction (XRPD) illustrated in Figure 2.

2. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide characterized by the post-DVS X-ray Powder Diffraction (XRPD) illustrated in Figure 2.

3. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide characterized by the initial Differential Scanning Calorimetry (DSC) illustrated in Figure 3.

4. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide characterized by the post-DVS Differential Scanning Calorimetry (DSC) illustrated in Figure 3.

5. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide characterized by the initial Thermogravimetric Analysis (TGA) illustrated in Figure 4.

6. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide characterized by the post-DVS Thermogravimetric Analysis (TGA) illustrated in Figure 4.

7. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide characterized by the initial X-ray Powder Diffraction (XRPD) illustrated in Figure 6.

8. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide characterized by the post-DVS X-ray Powder Diffraction (XRPD) illustrated in Figure 6.

9. A pharmaceutical composition comprising:

   (a) a therapeutically effective amount of a salt according to any of claims 1-8; and

   (b) at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient.